Literature DB >> 35188988

Not only toes and fingers: COVID vaccine-induced chilblain-like lesions of the knees.

A Bassi1, C Mazzatenta1, A Sechi2, M Cutrone3, V Piccolo4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35188988      PMCID: PMC9114987          DOI: 10.1111/jdv.18025

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   9.228


× No keyword cloud information.

Conflicts of interest

The authors have no financial obligations or conflict of interest to declare.

Funding source

None. Dear Editor, During the pandemic caused by SARS‐Cov‐2 infection, acral chilblain‐like lesions (CLL) have been commonly reported cutaneous manifestations of the disease even if their association with the infection has been discussed. , To control the diffusion of SARS‐CoV‐2 infection, a vaccination campaign is spreading around the world since December 2020; subsequently, several different cutaneous manifestations related to vaccines have been described. Here, we describe a 52‐year‐old woman presenting with purpuric lesions on the knees and lower third of her thighs (Fig. 1a,b). History revealed that the patient underwent the injection of the first dose of ©Moderna mRNA‐1273 vaccine on August 2021 and that the lesions had appeared about 7–10 days later. Lesions presented a cold surface and did not show any changes based on temperature. A slight itching sensation and painful walking were referred by the patient, who had never had similar lesions previously in her life. Dermoscopy showed a combination of linear vessels arranged in network fashion with multiple areas of coppery clods, the latter analogously observed in CLL of the toes (Fig. 1c). Patient was given topical steroids and oral cinnarizine (due to its vasodilator potential) for 2 weeks, and a slow improvement of the lesions was seen with also a fine ending desquamation of the purpuric lesions. Numerous skin manifestations associated with the virus have been largely discussed, as well as the cutaneous reactions to vaccines. The latter mostly included pain and swelling on the injection site and localized or diffuse erythematous or urticarial rash, usually associated with an itching sensation. All these lesions were usually transitory with a spontaneous resolution and not associated with systemic symptoms, except for rare cases of angio‐oedema and laryngospasm (usually in patients with a well‐noted allergic background). Purpuric lesions after vaccination were reported almost exclusively in association with ©Pfizer BNT162b2 mRNA vaccine, and included lesions on the eyelids, systemic purpuric rashes and cases of Henoch–Schonlein purpura. , , In our case, the primary lesions both clinically and dermoscopically were very similar to the previously reported cases of CLL after Pfizer vaccination , or SARS‐Cov‐2 infection which were, however, located on the hands and feet respectively. We report this particular and unusual localization of pernio‐like lesions on the knees, to point out that the appearance of these type of lesions after COVID‐19 vaccine cannot be considered a coincidence, also because all the patients reported in the literature had never suffered of similar lesions before facing COVID‐19 or its vaccine.
Figure 1

Pernio‐like lesions bilaterally located on the knees and lower part of the thighs (a–b), dermoscopy examination with the typical coppery background associated with dotted vessels (c).

Pernio‐like lesions bilaterally located on the knees and lower part of the thighs (a–b), dermoscopy examination with the typical coppery background associated with dotted vessels (c). The possible pathogenic mechanisms behind the association between COVID‐19 or SARS‐Cov‐2 vaccines and purpuric or CLL lesions are unclear. Currently, the most plausible hypothesis is that Covid‐19 related CLL may represent a virus‐induced interferonopaty associated with a strong activation of innate immune system and fast clearance of the virus and antibodies. The appearance of purpuric and/or CLL lesions after administration of different SARS‐Cov‐2 vaccines seems to suggest however that these lesions could be also considered as a particular form of exanthema induced by the activation of the immune system against the viral spike protein irrespectively of its natural o synthetic origin in predisposed individuals.
  10 in total

1.  BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2.

Authors:  V Piccolo; A Bassi; G Argenziano; C Mazzatenta; M Cutrone; I Neri; R Grimalt; T Russo
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-05-10       Impact factor: 9.228

2.  Chilblain-like lesions during the COVID-19 pandemic: should we really worry?

Authors:  Vincenzo Piccolo; Iria Neri; Francesca Manunza; Carlo Mazzatenta; Andrea Bassi
Journal:  Int J Dermatol       Date:  2020-06-04       Impact factor: 2.736

3.  Chilblain-Like Lesions during COVID-19 Pandemic: The State of the Art.

Authors:  Andrea Bassi; Teresa Russo; Giuseppe Argenziano; Carlo Mazzatenta; Elisabetta Venturini; Iria Neri; Vincenzo Piccolo
Journal:  Life (Basel)       Date:  2021-01-02

4.  Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine.

Authors:  Srikrishna V Malayala; Gisha Mohan; Deepa Vasireddy; Paavani Atluri
Journal:  Cureus       Date:  2021-03-25

5.  Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID-19 vaccine: another piece of SARS-CoV-2 skin puzzle?

Authors:  C Mazzatenta; V Piccolo; G Pace; I Romano; G Argenziano; A Bassi
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-05-28       Impact factor: 9.228

6.  Dermoscopy of chilblain-like lesions during the COVID-19 outbreak: A multicenter study on 10 patients.

Authors:  Vincenzo Piccolo; Andrea Bassi; Giuseppe Argenziano; Carlo Mazzatenta; Alba Guglielmo; Annalisa Patrizi; Iria Neri
Journal:  J Am Acad Dermatol       Date:  2020-09-30       Impact factor: 11.527

7.  Pernio-like skin lesions after the second dose of Pfizer-BioNTech COVID-19 vaccine.

Authors:  N Cameli; M Silvestri; M Mariano; S P Nisticò; A Cristaudo
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-24       Impact factor: 9.228

8.  Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.

Authors:  A Català; C Muñoz-Santos; C Galván-Casas; M Roncero Riesco; D Revilla Nebreda; A Solá-Truyols; P Giavedoni; M Llamas-Velasco; C González-Cruz; X Cubiró; R Ruíz-Villaverde; S Gómez-Armayones; M P Gil Mateo; D Pesqué; O Marcantonio; D Fernández-Nieto; J Romaní; N Iglesias Pena; L Carnero Gonzalez; J Tercedor-Sanchez; G Carretero; T Masat-Ticó; P Rodríguez-Jiménez; A M Gimenez-Arnau; M Utrera-Busquets; E Vargas Laguna; A G Angulo Menéndez; E San Juan Lasser; M Iglesias-Sancho; L Alonso Naranjo; I Hiltun; E Cutillas Marco; I Polimon Olabarrieta; S Marinero Escobedo; X García-Navarro; M J Calderón Gutiérrez; G Baeza-Hernández; L Bou Camps; T Toledo-Pastrana; A Guilabert
Journal:  Br J Dermatol       Date:  2021-09-21       Impact factor: 11.113

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.